Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine in Metastatic or Locally Advanced Urothelial Carcinoma
2024-516586-37-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in transitional cell carcinoma (TCC), sponsored by Medical University of Vienna. Primary endpoint: Maximum tolerated dose (MTD). Planned start Oct 2024; status: authorised.
02
Drugs
clofarabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-516586-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516586-37-00.